熱門資訊> 正文
Larimar Therapeutics股价为6000万美元
2025-07-30 12:09
- Larimar Therapeutics (NASDAQ:LRMR) has priced its underwritten public offering of 18.75 million shares at $3.20 per share, expecting to raise $60 million in gross proceeds.
- The company has also granted underwriters a 30-day option to buy up to an additional 2.81 million shares at the same price, excluding discounts.
- The offering, set to close around July 31, 2025, is being led by Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair.
- Proceeds will support the development of Larimar’s lead candidate, nomlabofusp, other pipeline programs, and general corporate purposes, including R&D and pre-commercial activities.
- LRMR --10.48% after hours to $3.16
- Source: Press Release
More on Larimar Therapeutics
- Larimar Therapeutics drops 20% as it announces public offering
- Seeking Alpha’s Quant Rating on Larimar Therapeutics
- Historical earnings data for Larimar Therapeutics
- Financial information for Larimar Therapeutics
推薦文章
華盛早報 | 美聯儲理事米蘭「首秀」，呼籲激進降息；英偉達漲近4%市值突破4.5萬億美元
美股機會日報 | 華爾街樂觀押注：利率降幅將遠超美聯儲預測！以太坊跳水重挫超5%，加密貨幣概念股BitMine盤前一度跌近10%
一圖看懂 | 兩隻易方達ETF開啟認購！入場門檻為1500港元
新股申購 | 博泰車聯今起招股！一手入場費2065.23港元
華盛早報 | 重磅！國新辦將舉行發佈會；巴菲特已清倉比亞迪，累計套利至少80億港元
美股「新寵」驟變：「昔日冷門」硬盤與內存站上AI風口 老牌存儲廠商業績股價齊飛
美聯儲政策路徑不確定性仍存 中期美債備受交易員青睞
特朗普的H-1B簽證10萬美元新規引發科技公司混亂
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
